Genprex collaborators share positive pre-clinical data linked to Oncoprex at American Association of Cancer Research meeting
Genprex Inc (NASDAQ:GNPX) announced Monday that its collaborators from the University of Texas MD Anderson Cancer Center presented positive preclinical data linked to the clinical-stage gene therapy company’s Oncoprex immunogene therapy for the treatment of a major type of lung cancer at the American Association of Cancer Research meeting.
In 2018, Genprex cemented a key research agreement with MD Anderson for the development of a cancer treatment using TUSC2 (Tumor Suppressor Candidate 2), the active agent in its flagship product Oncoprex in combination with immunotherapies.
READ: Genprex shares rise after CEO forecasts 2019 will be a landmark one for the gene-therapy company
Research has demonstrated that TUSC2 is a powerful tumor suppressor gene and has fewer side effects with less toxicity than other lung cancer drugs and can be administered systemically to cancer patients.
In layman’s terms, Oncoprex is basically the TUSC2 gene wrapped in a cholesterol nanoparticle that is engineered to target cancer cells.
At the American Association of Cancer Research meeting, MD Anderson shared a poster titled, “Development of an improved humanized patient-derived xenograft, Hu-PDX, mouse model for evaluation of antitumor immune response in lung cancer.”
The poster demonstrated that TUSC2 combined with a checkpoint blockade was more effective than a checkpoint blockade alone in increasing the survival of mice with human immune cells that had metastatic lung cancer. The data showed that TUSC2 treatment with the checkpoint inhibitor pembrolizumab “slowed tumor growth significantly.”
Pembrolizumab previously had no effect on tumor growth in non-humanized mice. The data also demonstrated the Hu-PDX model as an improved platform for evaluation of immunotherapy.
“This sophisticated model gets one step closer to recapitulating certain functions of the human immune response within a manageable scientific animal model and allows us to further test our hypotheses of how a more complex immune system could interact with aggressive cancers when primed by drugs, such as Oncoprex, in humans,” said Genprex Chief Operating Officer Julien L Pham in a statement.
READ: How Genprex took an abandoned pipeline drug and turned it into Oncoprex, an innovative treatment for non-small cell lung cancer
Pham said the data supported and solidified existing preclinical data showing that Oncoprex immunogene therapy is “synergistic with anti-PD1 therapy and could result in a stronger antitumor response” compared to either agent alone.
“It also demonstrates how Oncoprex could be used in combination with other immunotherapies as a viable treatment option for late-stage non-small cell lung cancer,” said Pham. “This sophisticated model gets one step closer to recapitulating certain functions of the human immune response within a manageable scientific animal model and allows us to further test our hypotheses of how a more complex immune system could interact with aggressive cancers when primed by drugs, such as Oncoprex, in humans.”
Genprex is a clinical-stage gene therapy company, which boasts Oncoprex, a flagship treatment for non-small cell lung cancer. Oncoprex works partly by interrupting the cell signaling pathways that prompt cancer cells to multiply as well as controlling the immune response against cancer cells.
Contact Uttara Choudhury at [email protected]
Follow her on Twitter: @UttaraProactive
Story by ProactiveInvestors
Source: https://www.proactiveinvestors.com/companies/news/218170/genprex-collaborators-share-positive-pre-clinical-data-linked-to-oncoprex-at-american-association-of-cancer-research-meeting-218170.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Please Help Support BeforeitsNews by trying our Natural Health Products below!
Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST
Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!
HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation.
Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.
MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser! Cleans out toxic buildup with oxygen!
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover - Reduces Smart Meter radiation by 96%! (See Video).